Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...
Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...
The essential thrombocythemia market is on a growth trajectory, driven by increasing diagnosis rates, aging population ...
Baricitinib, an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 indicated for the treatment of moderate to severe active RA, has been shown to provide greater improvements in patient-reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback